Table 3.
Summary of thrombocytopenia occurrence in studies of tirofiban.
| NO. | CITATION | YEAR | AGE | TOTAL TCP | EX TCP | CT TCP | SC | EX |
|---|---|---|---|---|---|---|---|---|
| 1 | Circulation. 1997;96(5):1445–1453 [14] | 1997 | ADULT | 22 | 12 | 10 | 4 | NA |
| 2 | N Engl J Med. 1998;338(21):1488–1497 [49] | 1998 | ADULT | 21 | 15 | 6 | 4 | NA |
| 3 | N Engl J Med. 1998;338(21):1498–1505 [13] | 1998 | ADULT | 24 | 18 | 6 | 1 | NA |
| 4 | N Engl J Med 2001;344:1888–1894 [12] | 2001 | NR | 70 | 12 | 58 | 1 | NA |
| 5 | J Am Coll Cardiol. 2004;44(1):14–19 [50] | 2004 | NR | 2 | 1 | 1 | 5 | 1 |
| 6 | Platelets. 2005;16(8):462–468 [51] | 2005 | ADULT | 11 | NR | NR | 3 | NA |
| 7 | JAMA. 2005;293(17):2109–2117 [52] | 2005 | NR | 9 | 1 | 8 | 1 | NA |
| 8 | JAMA. 2008;299(15):1788–1799 [53] | 2008 | NR | 18 | 3 | 15 | 1 | NA |
| 9 | Lancet 2008;372(9638):537–546 [54] | 2008 | ADULT | 19 | 10 | 9 | 4 | NA |
| 10 | Eur J Clin Pharmacol. 2012;68(5):821–832 [55] | 2012 | ADULT | 10 | 9 | 1 | 2 | NA |
| 11 | Stroke. 2021;52(12):3750–3758 [56] | 2021 | ADULT | 1 | 1 | 0 | 4 | NA |
Total TCP: Total number of patients with thrombocytopenia; EX TCP: The number of people in the experimental group that developed thrombocytopenia; CT TCP: The number of people in the control group that developed thrombocytopenia; SC: Score; EX: Exclusion; NR: Not Recorded; NA: Not Applicable.